Evaluation of intraindividual variability in hepatic CYP3A4 enzyme activity using endogenous markers in lung cancer patients treated with chemotherapeutic drugs and aprepitant

Evaluation of intraindividual variability in hepatic CYP3A4 enzyme activity using endogenous markers in lung cancer patients treated with chemotherapeutic drugs and aprepitant - Evaluation of intraindividual variability in hepatic CYP3A4 enzyme activity using endogenous markers in lung cancer patients treated with chemotherapeutic drugs and aprepitant

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016952

Enrollment

Registered

2015-03-27

Start date

2018-03-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer patients treated with chemotherapeutic drugs and aprepitant

Interventions

Chemotherapeutic drugs and aprepitant to lung cancer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Lung cancer patients 2)Patients aged > 20 years 3)PS(ECOG) of 0 to 2 4)Patients receiving 1st line chemotherapy to non-small cell lung cancer 5)Patients receiving highly emetogenic agent 6)Fulfill all following conditions T.Bil < 1.5 mg/dL AST (GOT) < 100 IU/L ALT (GPT) < 100 IU/L Cre < 1.5 mg/dL SpO2 > = 90% 7)Written informed consent from the patients

Exclusion criteria

Exclusion criteria: 1)Patients who required other chemotherapy 2)Patients who qre actively receiving inducer or inhibitor of CYP3A4 3)Patients who qre actively receiving androgen or estrogen preparation 4)Patients who qre actively receiving adrenal cortex hormone preparation without dexamethasone 5)Patients who qre actively receiving blood transfusion

Design outcomes

Primary

Measure	Time frame
CYP3A endogenous markers	—

Countries

Japan

Contacts

Public ContactHideyuki Hibino

Keio University Faculty of Pharmacy

sun-light-field@z7.keio.jp03-5400-2493

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026